Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Net Cash Flow (2016 - 2025)

Cytosorbents' Net Cash Flow history spans 15 years, with the latest figure at -$2.6 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$2.6 million for Q4 2025, down 14.8% from a year ago — trailing twelve months through Dec 2025 was -$3.5 million (up 39.59% YoY), and the annual figure for FY2025 was -$3.5 million, up 39.59%.
  • Net Cash Flow for Q4 2025 was -$2.6 million at Cytosorbents, down from -$2.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $5.7 million in Q4 2023 to a low of -$12.7 million in Q2 2022.
  • The 5-year median for Net Cash Flow is -$2.9 million (2021), against an average of -$3.2 million.
  • The sharpest move saw Net Cash Flow tumbled 340.15% in 2022, then surged 1137.17% in 2023.
  • Year by year, Net Cash Flow stood at -$7.2 million in 2021, then surged by 92.46% to -$546406.0 in 2022, then surged by 1137.17% to $5.7 million in 2023, then crashed by 140.55% to -$2.3 million in 2024, then decreased by 14.8% to -$2.6 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$2.6 million, -$2.5 million, and -$1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.